A Pivotal Phase III Study to Evaluate Overall Survival Using MABp1 as a Monotherapy in Metastatic Colorectal Cancer Patients With Cachexia
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall Survival
The difference in median overall survival will be compared between the two arms.
baseline to 18 months
No
Aminah Jatoi, M.D.
Study Chair
Mayo Clinic
United States: Food and Drug Administration
2012-PT023
NCT01767857
March 2013
December 2014
Name | Location |
---|---|
Mayo Clinic Cancer Center | Rochester, Minnesota 55905 |
Montefiore Medical Center | Bronx, New York 10467-2490 |
Moores UCSD Cancer Center | La Jolla, California 92093-0658 |
Mid Dakota Clinic | Bismarck, North Dakota 58501 |
Karmanos Cancer Institute | Detroit, Michigan 48201 |
Lewis Hall Singletary Oncology Center | Thomasville, Georgia 31792 |
Innovative Clinical Research Institute | Downey, California 90241 |
UT Medical Center Cancer Institute | Knoxville, Tennessee 37920 |